Targeting the B Cell in Rheumatoid Arthritis (Q34622760)

3 August 2017

title

Targeting the B cell in rheumatoid arthritis (English)

1 reference

3 August 2017

Targeting the B Cell in Rheumatoid Arthritis (English)

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

21 June 2024

1 reference

1

Stanley B Cohen

1 reference

3 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20732652

21 June 2024

publication date

1 August 2010

1 reference

full work available at URL

3 August 2017

https://api.elsevier.com/content/article/PII:S1521694209001429?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

https://api.elsevier.com/content/article/PII:S1521694209001429?httpAccept=text/plain

21 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

Best Practice & Research: Clinical Rheumatology

21 June 2024

published in

1 reference

3 August 2017

volume

24

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

553-563

1 reference

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

3 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

Suppression of proteoglycan-induced arthritis by anti-CD20 B Cell depletion therapy is mediated by reduction in autoantibodies and CD4+ T cell reactivity

21 June 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

The role of B cell abnormalities in the systemic autoimmune syndromes of lpr and gld mice

21 June 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

T cell activation in rheumatoid synovium is B cell dependent

21 June 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

Do self-perpetuating B lymphocytes drive human autoimmune disease?

21 June 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms

21 June 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis

21 June 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells

21 June 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

B lymphocytes induce the formation of follicular dendritic cell clusters in a lymphotoxin alpha-dependent fashion.

21 June 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains

21 June 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 June 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

21 June 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

21 June 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response

21 June 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

21 June 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis

21 June 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment

21 June 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis

21 June 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response

21 June 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment

21 June 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 June 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.

21 June 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis

21 June 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

21 June 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.

21 June 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

An Essential Role for BAFF in the Normal Development of B Cells Through a BCMA-Independent Pathway

21 June 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept

21 June 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

21 June 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production

21 June 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study

21 June 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.BERH.2009.11.006

21 June 2024

Identifiers

1 reference

3 August 2017

1 reference